Company Overview and News
2018-04-22 seekingalpha
Cash flow has not and is not projected to be able to meet both the preferred payments and the capital budget.
Upvote
Downvote
2018-04-20 marketrealist
The EIA released its natural gas storage report on April 19, 2018. The EIA reported that US natural gas inventories declined by 36 Bcf (billion cubic feet) to 1,299 Bcf on April 6–13, 2018. The inventories also declined by 808 Bcf or 38.3% year-over-year.
Upvote
Downvote
2018-04-20 seekingalpha
Chesapeake Energy is under appreciated by the market and in my view worth double the current price.
Upvote
Downvote
2018-04-19 marketrealist
Chesapeake Energy (CHK) stock fell 1.6% in the week ended April 17, 2018, during a volatile week for crude oil (UCO) prices. During the week, crude oil rose following geopolitical tensions, which, as the week progressed, eased a bit, causing crude oil prices to fall.
Upvote
Downvote
2018-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote
Downvote
2018-04-18 marketrealist
The natural gas rig count was at 192 in the week ending April 13, 2018, two less than in the previous week.
Upvote
Downvote
2018-04-17 247wallst
Stocks have been volatile in recent weeks, but after a strong gain on Monday, the major equity indices were indicated to have a strong open on Tuesday as well. The current bull market may now be over nine years old, but the trend of buying pullbacks is still more vulnerable to sellers, volatility and each major news headline than in 2017. Many investors are finding it hard to decide how they want their assets positioned for the rest of 2018 and beyond.
Upvote
Downvote
2018-04-16 channelnewsasia
Billionaire activist investor Carl Icahn nominated a five-person slate of his employees and business associates to replace the SandRidge Energy Inc board of directors on Monday, escalating his fight for control of the U.S. shale oil producer.
Upvote
Downvote
2018-04-13 oilvoice
The Shale Gas Market research report includes various topics like total market size, key market drivers, challenges, growth opportunities, Industry share, growth, demand, outlook etc. Furthermore it covers key market updates, the impact of regulations and technological updates in. The report addresses the need to stay updated in this competitive market conditions and this provides and comprehensive data for making strategies and decision so as to stimulate the market growth and profitability.
Upvote
Downvote
2018-04-11 sec.gov
Document Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-223189
Upvote
Downvote
2018-04-11 sec.gov
Document Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-223189
Upvote
Downvote
2018-04-11 sec.gov
Document Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-223189
Upvote
Downvote
2018-04-11 sec.gov
Document Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-223189
Upvote
Downvote
2018-04-11 sec.gov
Document Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-223189
Upvote
Downvote
2018-04-11 sec.gov
Document Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-223189
Upvote
Downvote
Related Articles
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET